Non–Clear Cell Renal Cancer: Features and Medical Management

View More View Less
  • a From the Tom Baker Cancer Center, Calgary, Alberta, Canada, and Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically with the introduction of targeted therapies against vascular endothelial growth factor and the mammalian target of rapamycin. Because patients with clear cell histology account for more than 80% of patients with RCC, little evidence is available on treating patients with non–clear cell histologies. Most clinical trials have excluded them from enrollment, except for a randomized study investigating temsirolimus. Many retrospective studies on the use of sunitinib, sorafenib, and temsirolimus in patients with non–clear cell histology have shown response rates ranging from 3.7% to 16%. Prospective studies in non–clear cell histologies are ongoing. Although response rates may not be as high as those in patients with clear cell histologies, targeted therapy may provide a clinically meaningful response. New investigational therapies are on the horizon for papillary RCC—the most-common non–clear cell RCC histology—targeting pathways specific to this histology, such as the c-MET pathway.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Dr. Heng has disclosed that he is on the advisory board for and a consultant with Pfizer Inc., Bayer AG, and Wyeth. Dr. Choueiri has disclosed that he is on the advisory board for and a consultant with Pfizer Inc., Bayer AG, Novartis AG, Abbott Laboratories, and Genentech, Inc.

Correspondence: Toni K. Choueiri, MD, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115. E-mail: Toni_Choueiri@dfci.harvard.edu
  • 1

    Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:24772490.

  • 2

    Kovacs G, Akhtar M, Beckwith BJ. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131133.

  • 3

    Kwak C, Park YH, Jeong CW. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 2007;95:317323.

    • Search Google Scholar
    • Export Citation
  • 4

    Cheville JC, Lohse CM, Zincke H. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612624.

    • Search Google Scholar
    • Export Citation
  • 5

    Beck SD, Patel MI, Snyder ME. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004;11:7177.

    • Search Google Scholar
    • Export Citation
  • 6

    Patard JJ, Leray E, Rioux-Leclercq N. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:27632771.

    • Search Google Scholar
    • Export Citation
  • 7

    Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537544.

    • Search Google Scholar
    • Export Citation
  • 8

    Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003;170:21632172.

  • 9

    Moch H, Gasser T, Amin MB. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604614.

    • Search Google Scholar
    • Export Citation
  • 10

    Pignot G, Elie C, Conquy S. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007;69:230235.

    • Search Google Scholar
    • Export Citation
  • 11

    Yang XJ, Tan MH, Kim HL. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005;65:56285637.

  • 12

    Ronnen EA, Kondagunta GV, Ishill N. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006;107:26172621.

  • 13

    Motzer RJ, Bacik J, Mariani T. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:23762381.

    • Search Google Scholar
    • Export Citation
  • 14

    Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 15

    Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.

  • 16

    Escudier B, Koralewski P, Pluzanska A. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3.

    • Search Google Scholar
    • Export Citation
  • 17

    Rini BI, Halabi S, Rosenberg JE. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:54225428.

    • Search Google Scholar
    • Export Citation
  • 18

    Choueiri TK, Plantade A, Elson P. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26:127131.

    • Search Google Scholar
    • Export Citation
  • 19

    Plimack ER, Jonasch E, Bekele BN. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a phase II study [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5112.

    • Search Google Scholar
    • Export Citation
  • 20

    Gore ME, Porta C, Oudard S. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5010

    • Search Google Scholar
    • Export Citation
  • 21

    Stadler WM, Figlin RA, Ernstoff MS. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5036.

    • Search Google Scholar
    • Export Citation
  • 22

    Beck J, Bajetta E, Escudier B. A large open label, non comparative, phase III study of the raf and VEGFR kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma [abstract]. Eur J Canc Suppl 2007;7:Abstract 244.

    • Search Google Scholar
    • Export Citation
  • 23

    Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

  • 24

    Dutcher JP, Szczylik C, Tannir N. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5033.

    • Search Google Scholar
    • Export Citation
  • 25

    Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res 2000;6:15181523.

    • Search Google Scholar
    • Export Citation
  • 26

    Pan C, Hussey M, Lara PN. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): final results from Southwest Oncology Group Study 0317 [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5051.

    • Search Google Scholar
    • Export Citation
  • 27

    Pavlovich CP, Walther MM, Eyler RA. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002;26:15421552.

  • 28

    Yamazaki K, Sakamoto M, Ohta T. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003;22:847852.

  • 29

    Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol 2006;33:534543.

  • 30

    Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology 1986;10:11311141.

  • 31

    Oudard S, Banu E, Vieillefond A. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 2007;177:16981702.

    • Search Google Scholar
    • Export Citation
  • 32

    de Peralta-Venturina M, Moch H, Amin M. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001;25:275284.

    • Search Google Scholar
    • Export Citation
  • 33

    Golshayan AR, George S, Heng DY. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009;27:235241.

    • Search Google Scholar
    • Export Citation
  • 34

    Nanus DM, Garino A, Milowsky MI. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:15451551.

    • Search Google Scholar
    • Export Citation
  • 35

    Haas N, Manola J, Pins M. ECOG 8802: phase II trial of doxorubicin (dox) and gemcitabine (gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features [abstract]. Presented at the 2009 Genitourinary Cancers Symposium; February 26–29, 2009; Orlando, Florida. Abstract 285.

    • Search Google Scholar
    • Export Citation
  • 36

    Escudier B, Ravaud A, Negrier S. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5025

    • Search Google Scholar
    • Export Citation
  • 37

    Eder JP, Heath E, Appleman L. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3526.

    • Search Google Scholar
    • Export Citation
  • 38

    Garcia A, Rosen L, Cunningham CC. Phase 1 study of ARQ 197, a selective inhibitor of the c-MET RTK in patients with metastatic solid tumors reaches recommended phase 2 dose [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3525.

    • Search Google Scholar
    • Export Citation
  • 39

    Srinivasan R, Choueiri TK, Vaishampayan U. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5103.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 168 70 2
PDF Downloads 96 42 2
EPUB Downloads 0 0 0